vs
Side-by-side financial comparison of AMBARELLA INC (AMBA) and Amphastar Pharmaceuticals, Inc. (AMPH). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $108.5M, roughly 1.7× AMBARELLA INC). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -13.9%, a 27.3% gap on every dollar of revenue. On growth, AMBARELLA INC posted the faster year-over-year revenue change (31.2% vs -1.8%). AMBARELLA INC produced more free cash flow last quarter ($31.4M vs $24.6M). Over the past eight quarters, AMBARELLA INC's revenue compounded faster (45.0% CAGR vs 3.2%).
Ambarella, Inc. is an American fabless semiconductor design company, focusing on low-power, high-definition (HD) and Ultra HD video compression, image processing, and computer vision processors. Ambarella's products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver and in-cabin monitoring, autonomous driving, and robotics applications. Ambarella's system on chips ...
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AMBA vs AMPH — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $108.5M | $183.1M |
| Net Profit | $-15.1M | $24.4M |
| Gross Margin | 59.6% | 46.8% |
| Operating Margin | -15.0% | 19.4% |
| Net Margin | -13.9% | 13.3% |
| Revenue YoY | 31.2% | -1.8% |
| Net Profit YoY | 37.2% | -35.7% |
| EPS (diluted) | $-0.35 | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $108.5M | $183.1M | ||
| Q3 25 | $95.5M | $191.8M | ||
| Q2 25 | $85.9M | $174.4M | ||
| Q1 25 | $84.0M | $170.5M | ||
| Q4 24 | $82.7M | $186.5M | ||
| Q3 24 | $63.7M | $191.2M | ||
| Q2 24 | $54.5M | $182.4M | ||
| Q1 24 | $51.6M | $171.8M |
| Q4 25 | $-15.1M | $24.4M | ||
| Q3 25 | $-20.0M | $17.4M | ||
| Q2 25 | $-24.3M | $31.0M | ||
| Q1 25 | $-20.2M | $25.3M | ||
| Q4 24 | $-24.1M | $38.0M | ||
| Q3 24 | $-34.9M | $40.4M | ||
| Q2 24 | $-37.9M | $37.9M | ||
| Q1 24 | $-60.6M | $43.2M |
| Q4 25 | 59.6% | 46.8% | ||
| Q3 25 | 58.9% | 51.4% | ||
| Q2 25 | 60.0% | 49.6% | ||
| Q1 25 | 60.0% | 50.0% | ||
| Q4 24 | 60.6% | 46.5% | ||
| Q3 24 | 60.8% | 53.3% | ||
| Q2 24 | 60.9% | 52.2% | ||
| Q1 24 | 59.8% | 52.4% |
| Q4 25 | -15.0% | 19.4% | ||
| Q3 25 | -23.0% | 13.2% | ||
| Q2 25 | -30.1% | 24.2% | ||
| Q1 25 | -30.2% | 21.9% | ||
| Q4 24 | -30.9% | 24.2% | ||
| Q3 24 | -56.9% | 29.8% | ||
| Q2 24 | -72.4% | 30.3% | ||
| Q1 24 | -80.8% | 27.9% |
| Q4 25 | -13.9% | 13.3% | ||
| Q3 25 | -20.9% | 9.0% | ||
| Q2 25 | -28.3% | 17.8% | ||
| Q1 25 | -24.1% | 14.8% | ||
| Q4 24 | -29.1% | 20.4% | ||
| Q3 24 | -54.8% | 21.1% | ||
| Q2 24 | -69.6% | 20.8% | ||
| Q1 24 | -117.4% | 25.1% |
| Q4 25 | $-0.35 | $0.51 | ||
| Q3 25 | $-0.47 | $0.37 | ||
| Q2 25 | $-0.58 | $0.64 | ||
| Q1 25 | $-0.48 | $0.51 | ||
| Q4 24 | $-0.58 | $0.74 | ||
| Q3 24 | $-0.85 | $0.78 | ||
| Q2 24 | $-0.93 | $0.73 | ||
| Q1 24 | $-1.51 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $174.1M | $282.8M |
| Total DebtLower is stronger | — | $608.7M |
| Stockholders' EquityBook value | $590.1M | $788.8M |
| Total Assets | $751.9M | $1.6B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $174.1M | $282.8M | ||
| Q3 25 | $142.7M | $276.2M | ||
| Q2 25 | $141.3M | $231.8M | ||
| Q1 25 | $144.6M | $236.9M | ||
| Q4 24 | $127.1M | $221.6M | ||
| Q3 24 | $153.9M | $250.5M | ||
| Q2 24 | $131.8M | $217.8M | ||
| Q1 24 | $144.9M | $289.6M |
| Q4 25 | — | $608.7M | ||
| Q3 25 | — | $608.6M | ||
| Q2 25 | — | $607.7M | ||
| Q1 25 | — | $603.9M | ||
| Q4 24 | — | $601.6M | ||
| Q3 24 | — | $596.4M | ||
| Q2 24 | — | $586.9M | ||
| Q1 24 | — | $594.0M |
| Q4 25 | $590.1M | $788.8M | ||
| Q3 25 | $576.5M | $776.7M | ||
| Q2 25 | $572.7M | $757.5M | ||
| Q1 25 | $561.4M | $751.3M | ||
| Q4 24 | $554.3M | $732.3M | ||
| Q3 24 | $547.6M | $727.7M | ||
| Q2 24 | $555.4M | $713.3M | ||
| Q1 24 | $559.9M | $672.4M |
| Q4 25 | $751.9M | $1.6B | ||
| Q3 25 | $706.4M | $1.7B | ||
| Q2 25 | $701.9M | $1.6B | ||
| Q1 25 | $689.0M | $1.6B | ||
| Q4 24 | $670.8M | $1.6B | ||
| Q3 24 | $650.3M | $1.5B | ||
| Q2 24 | $638.7M | $1.5B | ||
| Q1 24 | $657.7M | $1.6B |
| Q4 25 | — | 0.77× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | 0.82× | ||
| Q2 24 | — | 0.82× | ||
| Q1 24 | — | 0.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.3M | $32.9M |
| Free Cash FlowOCF − Capex | $31.4M | $24.6M |
| FCF MarginFCF / Revenue | 29.0% | 13.4% |
| Capex IntensityCapex / Revenue | 2.7% | 4.5% |
| Cash ConversionOCF / Net Profit | — | 1.35× |
| TTM Free Cash FlowTrailing 4 quarters | $64.3M | $121.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.3M | $32.9M | ||
| Q3 25 | $5.5M | $52.6M | ||
| Q2 25 | $14.8M | $35.6M | ||
| Q1 25 | $25.4M | $35.1M | ||
| Q4 24 | $6.6M | $29.0M | ||
| Q3 24 | $16.7M | $60.0M | ||
| Q2 24 | $-15.0M | $69.1M | ||
| Q1 24 | $-4.0M | $55.3M |
| Q4 25 | $31.4M | $24.6M | ||
| Q3 25 | $1.4M | $47.2M | ||
| Q2 25 | $10.2M | $25.0M | ||
| Q1 25 | $21.2M | $24.4M | ||
| Q4 24 | $4.1M | $16.6M | ||
| Q3 24 | $14.2M | $46.2M | ||
| Q2 24 | $-16.1M | $63.1M | ||
| Q1 24 | $-6.0M | $46.5M |
| Q4 25 | 29.0% | 13.4% | ||
| Q3 25 | 1.4% | 24.6% | ||
| Q2 25 | 11.9% | 14.3% | ||
| Q1 25 | 25.3% | 14.3% | ||
| Q4 24 | 5.0% | 8.9% | ||
| Q3 24 | 22.2% | 24.1% | ||
| Q2 24 | -29.5% | 34.6% | ||
| Q1 24 | -11.6% | 27.1% |
| Q4 25 | 2.7% | 4.5% | ||
| Q3 25 | 4.3% | 2.8% | ||
| Q2 25 | 5.3% | 6.1% | ||
| Q1 25 | 5.0% | 6.3% | ||
| Q4 24 | 3.0% | 6.7% | ||
| Q3 24 | 4.0% | 7.2% | ||
| Q2 24 | 2.1% | 3.3% | ||
| Q1 24 | 3.7% | 5.1% |
| Q4 25 | — | 1.35× | ||
| Q3 25 | — | 3.03× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | — | 0.76× | ||
| Q3 24 | — | 1.48× | ||
| Q2 24 | — | 1.82× | ||
| Q1 24 | — | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMBA
| TW | $76.0M | 70% |
| Asia Pacific Other Than Taiwan | $20.2M | 19% |
| North America Other Than United States | $7.4M | 7% |
| Other | $5.0M | 5% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
